Home > Gastroenterology > DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By
Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GI 2022
Trial
Phase 2, DESTINY-Gastric01
The final results of the phase 2 DESTINY-Gastric01 trial showed that trastuzumab deruxtecan (T-DXd) was superior to a standard PC chemotherapy regimen in patients with HER2-positive advanced gastric or gastroesophageal cancer. Also, the updated safety data were consistent with the primary analysis of this study [1]. The open-label, multicentre, phase 2 DESTINY-Gastric01 trial (NCT03329690) included 188 patients with HER2-positive advanced gastric or gastroesophageal cancer who had undergone 2 or more prior lines of therapy, including fluoropyrimidine and a platinum agent. Participants were randomised 2:1 to T-DXd, 6.4 mg/kg every 3 weeks, or a standard PC chemotherapy regimen (i.e. irinotecan and/or paclitaxel). In the primary analysis, T-DXd outperformed PC chemotherapy on the primary endpoint of ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on